1. Home
  2. ARMP vs LOAN Comparison

ARMP vs LOAN Comparison

Compare ARMP & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • LOAN
  • Stock Information
  • Founded
  • ARMP N/A
  • LOAN 1989
  • Country
  • ARMP United States
  • LOAN United States
  • Employees
  • ARMP N/A
  • LOAN N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • LOAN Real Estate Investment Trusts
  • Sector
  • ARMP Health Care
  • LOAN Real Estate
  • Exchange
  • ARMP Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • ARMP 52.1M
  • LOAN 58.1M
  • IPO Year
  • ARMP N/A
  • LOAN 1999
  • Fundamental
  • Price
  • ARMP $2.22
  • LOAN $5.36
  • Analyst Decision
  • ARMP Strong Buy
  • LOAN
  • Analyst Count
  • ARMP 1
  • LOAN 0
  • Target Price
  • ARMP $9.00
  • LOAN N/A
  • AVG Volume (30 Days)
  • ARMP 18.4K
  • LOAN 20.8K
  • Earning Date
  • ARMP 08-12-2025
  • LOAN 07-21-2025
  • Dividend Yield
  • ARMP N/A
  • LOAN 8.52%
  • EPS Growth
  • ARMP N/A
  • LOAN N/A
  • EPS
  • ARMP N/A
  • LOAN 0.48
  • Revenue
  • ARMP $4,699,000.00
  • LOAN $7,291,468.00
  • Revenue This Year
  • ARMP $8.43
  • LOAN N/A
  • Revenue Next Year
  • ARMP N/A
  • LOAN $4.41
  • P/E Ratio
  • ARMP N/A
  • LOAN $11.21
  • Revenue Growth
  • ARMP 14.24
  • LOAN N/A
  • 52 Week Low
  • ARMP $0.90
  • LOAN $4.74
  • 52 Week High
  • ARMP $3.42
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 63.56
  • LOAN 54.28
  • Support Level
  • ARMP $1.93
  • LOAN $5.36
  • Resistance Level
  • ARMP $2.24
  • LOAN $5.85
  • Average True Range (ATR)
  • ARMP 0.16
  • LOAN 0.13
  • MACD
  • ARMP 0.03
  • LOAN 0.01
  • Stochastic Oscillator
  • ARMP 104.55
  • LOAN 43.84

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: